The Deepbridge Life Sciences EIS team prepares and reviews investment opportunities sourced from a wide dealflow network. Generally, Deepbridge seeks investment opportunities that exhibit the following qualities:
- A focus on life sciences and medical device technology;
- Significant market potential with clear need and market growth;
- Provide a solution to a recognised clinical or healthcare need;
- Innovation-driven products that have the potential to create new market segments or displace current technologies;
- Medical technology businesses with a clear and realistic path to commercialisation;
- Robust intellectual property which may provide patented or patentable IP protection
- Passionate, energetic, experienced and aligned founding team;
- Clear exit strategy to be implemented within 4-5 years with alignment of interests with our stakeholders.
Deepbridge will take an active executive role on the Board of the investee companies to utilise the strengths and commercial experience that the Deepbridge team possess in order to accelerate the growth of the investee company.
For more information on the Deepbridge Life Sciences EIS, please click here.
Dr Savvas Neophytou, Partner & Head of Life Sciences, Deepbridge Capital.
- February 2026 (1)
- January 2026 (3)
- December 2025 (2)
- November 2025 (3)
- October 2025 (1)
- August 2025 (2)
- June 2025 (2)
- May 2025 (1)
- March 2025 (1)
- February 2025 (1)
- January 2025 (1)
- December 2024 (1)
- November 2024 (1)
- October 2024 (4)
- September 2024 (4)
- August 2024 (4)
- July 2024 (1)
- June 2024 (3)